Extended-pulsed fidaxomicin versus vancomycin for Clostridium difficile infection in patients 60 years and older (EXTEND): a randomised, controlled, open-label, phase 3b/4 trial

Open Label ◽

Open Label Phase ◽

Sub-group Analyses from the EXTEND Study: a Randomised, Controlled, Open-Label, Phase III/IV Study Comparing the Efficacy of Extended-Pulsed Fidaxomicin with Standard Vancomycin Therapy for Sustained Clinical Cure of Clostridium difficile Infection in an Older Population

Open Forum Infectious Diseases ◽

10.1093/ofid/ofx163.1403 ◽

2017 ◽

Vol 4 (suppl_1) ◽

pp. S539-S540

Author(s):

Oliver A Cornely ◽

Maria J G T Vehreschild ◽

Nicholas Adomakoh ◽

Areti Georgopali ◽

Andreas Karas ◽

...

Keyword(s):

Clostridium Difficile ◽

Clinical Cure ◽

Phase Iii ◽

Vancomycin Therapy ◽

Open Label ◽

Older Population ◽

Open Label Phase ◽

Vancomycin followed by Fecal Microbiota Transplantation Versus Vancomycin for Initial Clostridium difficile Infection: An Open-label Randomised Controlled Trial

10.26226/morressier.59a6b344d462b80290b54594 ◽

2017 ◽

Author(s):

Siew Chien Ng

Keyword(s):

Clostridium Difficile ◽

Fecal Microbiota Transplantation ◽

Controlled Trial ◽

Fecal Microbiota ◽

Open Label ◽

An Exploratory, Open-Label, Oligo-Center Study to Evaluate the Safety, Efficacy, and Pharmacokinetics of Intravenous DNV3837 in Subjects With Clostridium Difficile Infection

Case Medical Research ◽

10.31525/ct1-nct03988855 ◽

2019 ◽

Author(s):

Keyword(s):

Clostridium Difficile ◽

Open Label ◽

Center Study

Faculty Opinions recommendation of Atezolizumab versus docetaxel for patients with previously treated non-small-cell lung cancer (POPLAR): a multicentre, open-label, phase 2 randomised controlled trial.

Faculty Opinions – Post-Publication Peer Review of the Biomedical Literature ◽

10.3410/f.726215272.793539632 ◽

2017 ◽

Author(s):

Patrick Nana-Sinkam

Keyword(s):

Lung Cancer ◽

Controlled Trial ◽

Small Cell ◽

Phase 2 ◽

Small Cell Lung ◽

Open Label ◽

Open Label Phase ◽

Previously Treated ◽

Faculty Opinions recommendation of Multiple-dose versus single-dose ivermectin for Strongyloides stercoralis infection (Strong Treat 1 to 4): a multicentre, open-label, phase 3, randomised controlled superiority trial.

Faculty Opinions – Post-Publication Peer Review of the Biomedical Literature ◽

10.3410/f.736675072.793566801 ◽

2019 ◽

Author(s):

Pedro Legua Leiva

Keyword(s):

Single Dose ◽

Multiple Dose ◽

Strongyloides Stercoralis ◽

Open Label ◽

Phase 3 ◽

Open Label Phase ◽

Superiority Trial ◽

Upfront FOLFOXIRI Plus Bevacizumab and Reintroduction after Progression versus mFOLFOX6 Plus Bevacizumab Followed by FOLFIRI Plus Bevacizumab in the Treatment of Patients with Metastatic Colorectal Cancer (TRIBE2): A Multicentre, Open-Label, Phase 3, Randomised Controlled Trial by GONO

SSRN Electronic Journal ◽

10.2139/ssrn.3478102 ◽

2019 ◽

Author(s):

Chiara Cremolini ◽

Carlotta Antoniotti ◽

Daniele Rossini ◽

Sara Lonardi ◽

Fotios Loupakis ◽

...

Keyword(s):

Colorectal Cancer ◽

Metastatic Colorectal Cancer ◽

Controlled Trial ◽

Open Label ◽

Phase 3 ◽

Open Label Phase ◽

Atezolizumab plus bevacizumab versus sunitinib in patients with previously untreated metastatic renal cell carcinoma (IMmotion151): a multicentre, open-label, phase 3, randomised controlled trial

The Lancet ◽

10.1016/s0140-6736(19)30723-8 ◽

2019 ◽

Vol 393 (10189) ◽

pp. 2404-2415 ◽

Cited By ~ 233

Author(s):

Brian I Rini ◽

Thomas Powles ◽

Michael B Atkins ◽

Bernard Escudier ◽

David F McDermott ◽

...

Keyword(s):

Renal Cell Carcinoma ◽

Cell Carcinoma ◽

Metastatic Renal Cell Carcinoma ◽

Renal Cell ◽

Controlled Trial ◽

Open Label ◽

Phase 3 ◽

Open Label Phase ◽

Anti-C5a antibody IFX-1 (vilobelimab) treatment versus best supportive care for patients with severe COVID-19 (PANAMO): an exploratory, open-label, phase 2 randomised controlled trial

The Lancet Rheumatology ◽

10.1016/s2665-9913(20)30341-6 ◽

2020 ◽

Vol 2 (12) ◽

pp. e764-e773 ◽

Cited By ~ 9

Author(s):

Alexander P J Vlaar ◽

Sanne de Bruin ◽

Matthias Busch ◽

Sjoerd A M E G Timmermans ◽

Ingeborg E van Zeggeren ◽

...

Keyword(s):

Supportive Care ◽

Controlled Trial ◽

Best Supportive Care ◽

Phase 2 ◽

Open Label ◽

Open Label Phase ◽

Convalescent plasma in the management of moderate covid-19 in adults in India: open label phase II multicentre randomised controlled trial (PLACID Trial)

BMJ ◽

10.1136/bmj.m4232 ◽

2020 ◽

pp. m4232

Keyword(s):

Phase Ii ◽

Controlled Trial ◽

Open Label ◽

Open Label Phase ◽

Ceritinib versus chemotherapy in patients with ALK-rearranged non-small-cell lung cancer previously given chemotherapy and crizotinib (ASCEND-5): a randomised, controlled, open-label, phase 3 trial

The Lancet Oncology ◽

10.1016/s1470-2045(17)30339-x ◽

2017 ◽

Vol 18 (7) ◽

pp. 874-886 ◽

Cited By ~ 216

Author(s):

Alice T Shaw ◽

Tae Min Kim ◽

Lucio Crinò ◽

Cesare Gridelli ◽

Katsuyuki Kiura ◽

...

Keyword(s):

Lung Cancer ◽

Small Cell Lung Cancer ◽

Cell Lung Cancer ◽

Small Cell ◽

Small Cell Lung ◽

Open Label ◽

Phase 3 ◽

Open Label Phase ◽